- Tous > Medicine Access and Rational Use > Pricing
- Tous > Medicine Access and Rational Use > Selection
- Mots-clés > access - high cost medicines
- Mots-clés > anti-cancer medicines
- Mots-clés > cancer and cancer therapeutics
- Mots-clés > cancer medicines - availability and affordability
- Mots-clés > cancer medicines - pricing
- Mots-clés > Essential Medicines List (EML)
- Mots-clés > prices / pricing policy
- Mots-clés > reimbursement list
- Mots-clés > research - cost of drug development
- Mots-clés > selection of medicines
(2019; 11 pages)
Faruqui N, et al. BMJ Glob Health 2019;4:e001379. doi:10.1136/bmjgh-2018-001379
Introduction: Limited access to essential medicines (EMs) for treating chronic diseases is a major challenge in low-income and middle-income countries. Although India is the largest manufacturer of generic medicines, there is a paucity of information on availability, price and affordability of anti-neoplastic EMs, which this study evaluates.
Methods: Using a modified WHO/Health Action International methodology, data were collected on availability and price of 33 strength-specific anti-neoplastic EMs and 4 non-cancer EMs. Seven ‘survey anchor’ hospitals (4 public and 3 private) and 32 private-sector retail pharmacies were surveyed. Median price ratios (MPRs) were calculated by comparing consumer prices with international reference prices (IRPs).
Results: On average, across survey anchor areas (hospital and private-sector retail pharmacies combined), the mean availability of anti-neoplastic EMs and noncancer medicines was 70% and 100%, respectively. Mean availability of anti-neoplastic EMs was 38% in private-sector retail pharmacies, 43% in public hospital pharmacies and 71% in private hospital pharmacies. Median MPR of lowest-priced generic versions was 0.71 in retail pharmacies. The estimated cost of chemotherapy medicines needed for treating a 30 kg child with standardrisk leukaemia was INR 27 850 (US$442) and INR 17 500 (US$278) for Hodgkin’s lymphoma, requiring 88 and 55 days’ wages, respectively, for the lowest paid government worker.
Conclusion: Most anti-neoplastic EMs are found in survey anchor areas, however, mean availability was less than non-cancer medicines; not meeting the WHO target of 80%. Medicine prices were relatively low in New Delhi compared with IRPs. However, the cost of chemotherapy medicines seems unaffordable in the local context.